Development asset linked to Cogent Biosciences in public FDA and regional records.
pharma · Lymphoma · Gastrointestinal Stromal Tumors · COGT
Cogent Biosciences
Cogent Biosciences drug portfolio — 8 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
275 Wyman Street, 3rd Floor, Waltham, Massachusetts 02451, US HQ
2014 Founded
283 Employees
Public company Type
COGT · NYSE Ticker
Company details
- Status
- Public
- HQ
- 275 Wyman Street, 3rd Floor, Waltham, Massachusetts 02451, US
- Founded
- 2014
- Employees
- 283
- Programs
- 13
- Drugs
- 8
- Patents
- 10
Cogent Biosciences pipeline
Portfolio lens on 8 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Cogent Biosciences drug portfolio — 8 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Cogent Biosciences in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Gonadotropin-releasing hormone receptor.
- Target
- Gonadotropin-releasing hormone receptor
- Mechanism
- Gonadotropin-releasing hormone receptor agonist
-
Development asset linked to Cogent Biosciences in public FDA and regional records.
-
sunitinib
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Cogent Biosciences's portfolio. Molecular target: Macrophage colony-stimulating factor 1 receptor.
- Target
- Macrophage colony-stimulating factor 1 receptor
- Mechanism
- Vascular endothelial growth factor receptor inhibitor
-
Development asset linked to Cogent Biosciences in public FDA and regional records.
-
Development asset linked to Cogent Biosciences in public FDA and regional records.
-
Development asset linked to Cogent Biosciences in public FDA and regional records.